Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)

Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)

vilazodoneVilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year.  The drug will be available in 10 mg, 20 mg and 40 mg dosage forms.

Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood. Fatigue, irritability, loss of sleep and appetite are just some of its symptoms. The disorder is not new and is currently treated by antidepressants that act on the serotonin and norepinephrine receptors and the monoamine oxidase enzyme (MAO). Although proven effective and safe, these drugs are not without side effects that seriously undermine a patient’s compliance to therapy. Clinical Data Inc. recently developed the drug, Vilazodone (Viibryd) to address these shortcomings. According to the company, Vilazodone did not cause a body weight change nor altered hepatic and cardiac parameters.

depressionVilazodone is a combination of an SSRI and 5HT1A serotonin receptor partial agonist that has recently gained FDA approval for the treatment of MDD. Although its mechanism of action has not been fully understood yet the researchers at Clinical Data Inc. thought that its pharmacologic action stems from the drug’s ability to enhance serotonergic activity in the patient’s brain. Carol R. Reed, executive vice president of Clinical Data, said that it will provide a new choice for clinicians since the drugs currently used to treat the disorder are known to cause intolerable side effects which accounts for a great percentage of discontinued and unsuccessful drug therapies.

According to the published clinical trials data, Vilazodone is safe and effective compared to placebo. The recommended starting dose is 10 mg in the first week gradually titrated up to 20 mg in the second week and subsequently 40 mg thereafter. Like other antidepressant drugs available in the market, it needs to be gradually tapered before a complete cessation of therapy is achieved.

LGM Pharma is hot on the tracks of this new drug development. Since gaining approval, LGM Pharma has become the preferred supplier of Vilazodone CAS# 163521-12-8 by pharmaceutical companies who are currently engaged in its R&D.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service